Cargando…
Management of hepatitis C genotype 4 in the directly acting antivirals era
Genotype 4 chronic hepatitis C (G4 HCV) accounts for 13% of worldwide HCV infections; with 10 million people infected with the virus across the world. Up to the end of 2013, the only treatment option for G4 HCV was treatment with pegylated interferon and ribavirin for 24–48 weeks. Since late 2013, t...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051320/ https://www.ncbi.nlm.nih.gov/pubmed/27752338 http://dx.doi.org/10.1136/bmjgast-2016-000112 |
_version_ | 1782458062081097728 |
---|---|
author | Hathorn, Emma Elsharkawy, Ahmed M |
author_facet | Hathorn, Emma Elsharkawy, Ahmed M |
author_sort | Hathorn, Emma |
collection | PubMed |
description | Genotype 4 chronic hepatitis C (G4 HCV) accounts for 13% of worldwide HCV infections; with 10 million people infected with the virus across the world. Up to the end of 2013, the only treatment option for G4 HCV was treatment with pegylated interferon and ribavirin for 24–48 weeks. Since late 2013, treatment of G4 HCV has been transformed by the licensing of many directly acting antiviral agents (DAA). It is an exciting time to be involved in the management of HCV generally and G4 particularly. Interferon-free DAA regimens are now a reality for G4 HCV. This review will highlight these developments and discuss the data behind the use of these drugs. It will also highlight future regimens that are likely to be available over the coming years. |
format | Online Article Text |
id | pubmed-5051320 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-50513202016-10-17 Management of hepatitis C genotype 4 in the directly acting antivirals era Hathorn, Emma Elsharkawy, Ahmed M BMJ Open Gastroenterol Infection Genotype 4 chronic hepatitis C (G4 HCV) accounts for 13% of worldwide HCV infections; with 10 million people infected with the virus across the world. Up to the end of 2013, the only treatment option for G4 HCV was treatment with pegylated interferon and ribavirin for 24–48 weeks. Since late 2013, treatment of G4 HCV has been transformed by the licensing of many directly acting antiviral agents (DAA). It is an exciting time to be involved in the management of HCV generally and G4 particularly. Interferon-free DAA regimens are now a reality for G4 HCV. This review will highlight these developments and discuss the data behind the use of these drugs. It will also highlight future regimens that are likely to be available over the coming years. BMJ Publishing Group 2016-09-30 /pmc/articles/PMC5051320/ /pubmed/27752338 http://dx.doi.org/10.1136/bmjgast-2016-000112 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Infection Hathorn, Emma Elsharkawy, Ahmed M Management of hepatitis C genotype 4 in the directly acting antivirals era |
title | Management of hepatitis C genotype 4 in the directly acting antivirals era |
title_full | Management of hepatitis C genotype 4 in the directly acting antivirals era |
title_fullStr | Management of hepatitis C genotype 4 in the directly acting antivirals era |
title_full_unstemmed | Management of hepatitis C genotype 4 in the directly acting antivirals era |
title_short | Management of hepatitis C genotype 4 in the directly acting antivirals era |
title_sort | management of hepatitis c genotype 4 in the directly acting antivirals era |
topic | Infection |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5051320/ https://www.ncbi.nlm.nih.gov/pubmed/27752338 http://dx.doi.org/10.1136/bmjgast-2016-000112 |
work_keys_str_mv | AT hathornemma managementofhepatitiscgenotype4inthedirectlyactingantiviralsera AT elsharkawyahmedm managementofhepatitiscgenotype4inthedirectlyactingantiviralsera |